SCYNEXIS INC (SCYX): Nasdaq/NYSE listing notice — SCYNEXIS receives Nasdaq bid price deficiency notice; has until Dec 17 to regain compliance

SCYNEXIS INC

Received Nasdaq letter on June 20, 2025, for bid price <$1 for 30 consecutive business days.
Has 180 calendar days until December 17, 2025, to regain compliance with minimum bid price.
May transfer to Nasdaq Capital Market for additional 180-day compliance period if needed.
Will evaluate options including potential reverse stock split to cure deficiency.
No assurance of regaining compliance; could face delisting if not cured.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SCYNEXIS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

June 20, 2025, SCYNEXIS, Inc. (“SCYNEXIS”) received a letter from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying SCYNEXIS that, for the last 30 consecutive business days, the closing bid price for SCYNEXIS’s common stock was below the $1.00 per share minimum required for continued listing on the Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1). The letter from Nasdaq has no immediate effect on the listing of SCYNEXIS’s common stock on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), SCY

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SCYNEXIS INC filing history →

Source: SEC EDGAR

accession 0000950170-25-090374

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.